Advances in use of the CRISPR genome editing technology have been arriving at breakneck speed. But even as the first clinical trials of the technique are expected to start before the end of the year, scientists have found that CRISPR might in some circumstances pose unexpected risks to patients.

During HUBweek, STAT’s Sharon Begley — along with a panel of experts — will explore the newest forms and uses of CRISPR, its potential to cure now-incurable diseases, and the challenges of turning a revolutionary lab technique into a therapy. Coffee and snacks will be provided. Register below to reserve a seat.